[go: up one dir, main page]

US20090131457A1 - Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders - Google Patents

Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders Download PDF

Info

Publication number
US20090131457A1
US20090131457A1 US12/227,314 US22731407A US2009131457A1 US 20090131457 A1 US20090131457 A1 US 20090131457A1 US 22731407 A US22731407 A US 22731407A US 2009131457 A1 US2009131457 A1 US 2009131457A1
Authority
US
United States
Prior art keywords
methyl
pyrazolo
amino
pyrimidin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/227,314
Other languages
English (en)
Inventor
Ian Bruce
Judy Fox Hayler
Graham Charles Bloomfield
Lee Edwards
Brian Cox
Catherine Howsham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36687588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20090131457(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of US20090131457A1 publication Critical patent/US20090131457A1/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAYLER, JUDY FOX, BLOOMFIELD, GRAHAM CHARLES, BRUCE, IAN, COX, BRIAN, EDWARDS, LEE, HOWSHAM, CATHERINE
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to organic compounds, their preparation and their use as pharmaceuticals.
  • the present invention provides use of a compound of formula (I)
  • R 1 is C 1 -C 3 -alkyl, optionally substituted by one to seven fluoro groups
  • R 2 is a 5-6 membered hetaroaryl group, or R 2 is phenyl having the substitution pattern
  • the 5-6 membered heteroaryl group is optionally fused by phenyl, a further 5-6 membered heteroaryl group, a C 4 -C 6 carbocyclic group or a 5-6 membered heterocyclyl group and where the R 2 phenyl is optionally fused at R 4 —R 5 , R 5 —R 6 , R 6 —R 7 or R 7 —R 8 by a further phenyl, a 5-6 membered heteroaryl group, a C 4 -C 6 carbocyclic group or a 5-6 membered heterocyclyl group, where the 5-6 membered heteroaryl or fused 5-6 membered heteroaryl, phenyl or the fused phenyl group is independently optionally substituted by one or more groups selected from List X;
  • List X represents hydroxyl, cyano, nitro, C 1 -C 8 -alkyl, C 1 -C 8 -alkenyl, C 1 -C 8 -
  • a method of treating a disorder in which pi3 kinase is implicated in a patient comprising administering an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • the disorder is selected from a respiratory disorder, such as asthma or COPD.
  • a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof with the proviso that the compounds N-[4-[6-(ethylamino)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-N′-[2-fluoro-5-(trifluoromethyl)phenyl urea and [4-(6-amino-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl]-1,1-dimethyl carbamic acid ester are excluded.
  • the present invention provides a compound of formula (IA):
  • R 1a is C 1 -C 3 -alkyl, optionally substituted by one to seven fluoro groups;
  • R 2a a 5-6 membered hetaroaryl group substituted by one or more groups selected from List Xa, or R 2 is phenyl having the substitution pattern,
  • phenyl may be fused at ea R 5a , R 6a —R 7a or R 7a —R 8a by a 5-6 membered heteroaryl group, a C 4 -C 6 carbocyclic group or a 5-6 membered heterocyclyl group, where the phenyl or the fused phenyl group may be optionally substituted by one or more groups selected from List Xa;
  • List Xa represents hydroxyl, cyano, nitro, C 1 -C 8 -alkyl, C 1 -C 8 -alkenyl, C 1 -C 8 -alkynyl, C 1 -C 8 -alkoxy, C 1 -C 8 -alkenyloxy, C 1 -C 8 -alkynyloxy, —O—(C 1 -C 4 -alkylene)-R 9a , —(C 2 -C 4 -alkylene)-R 10a , halogen, C
  • Alkyl, alkenyl, alkynyl, alkylene, and alkoxy groups, containing the requisite number of carbon atoms can be unbranched or branched.
  • alkyl include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl and t-butyl.
  • alkoxy include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, sec-butoxy and t-butoxy.
  • alkylene include methylene, 1,1-ethylene, 1,2-ethylene, 1,1-propylene, 1,2-propylene, 1,3-propylene and 2,2-propylene.
  • a “hydrocarbon group optionally substituted” refers to replacement of a C—H bond by the requisite bond.
  • the substituent is a halogen
  • the group formed is defined as a C 1 -C 8 -haloalkyl.
  • the substituent is fluoro
  • common haloalkyl groups are trifluoroalkyl, 2,2,2-trifluoroethyl or 2,2,2,1,1-pentafluoroethyl groups.
  • Carbocyclic group denotes a hydrocarbon ring having the requisite number of carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl.
  • Halogen or “halo” may be fluorine, chlorine, bromine or iodine.
  • a heterocyclyl group refers to a saturated or partially unsaturated ring comprising one or more O, N or S heteratoms.
  • Specific examples of heterocyclyl groups include [1,3]dioxolane, [1,4]dioxane, oxiranyl, aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, morpholino, thiomorpholinyl, piperazinyl, azepinyl, oxapinyl, oxazepinyl and diazepinyl.
  • a heteroaryl group refers to an aromatic ring comprising one or more O, N or S heteroatoms.
  • heteroaryl groups include pyridyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazoyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl and tetrazolyl, and bicyclic heteroaryl or phenyl fused by heteroaryl groups include indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzofuranyl.
  • R 1 is suitably methyl or trifluoromethyl, preferably methyl.
  • the R 2 ring is suitably substituted.
  • pyridyl e.g. 3-pyridyl or 4-pyridyl, optionally substituted by halogen, e.g. fluoro, trifluoromethyl, methylsulfonyl or C 1 -C 8 -alkoxy, e.g. methoxy
  • thienyl e.g. 2-thienyl, optionally substituted by C 1 -C 8 -alkylcarbonyl, e.g. acetyl, or halo, e.g. chloro
  • isoxazolyl e.g.
  • 4-isoxazolyl optionally substituted by one or two C 1 -C 8 -alkyl, e.g. 3,5-dimethyl, (iv) furanyl, e.g. 2-furanyl, or (v) pyrimidyl, e.g. 5-pyrimidyl, optionally substituted by a 5-6 membered heterocyclyl, e.g. piperazinyl, e.g. 2-piperazinyl or one or two C 1 -C 8 -alkoxy, e.g. 2-methoxy or 2,4 di-methoxy.
  • C 1 -C 8 -alkyl e.g. 3,5-dimethyl
  • furanyl e.g. 2-furanyl
  • pyrimidyl e.g. 5-pyrimidyl
  • a 5-6 membered heterocyclyl e.g.
  • piperazinyl e.g. 2-piperazinyl or one or two C 1 -C 8
  • R 2 phenyl ring is fused by a further phenyl to form a naphthyl group
  • the ring is suitably fused at R 7 —R 8 to form a 1-naphthyl
  • the resulting naphthyl is optionally substituted, e.g. by C 1 -C 8 -alkoxy, e.g. ethoxy, e.g. 2-ethoxy.
  • R 2 phenyl ring is fused by a 5-6 membered heteroaryl
  • the ring is suitably fused at R 5 —R 6 , R 6 —R 7 , or R 7 —R 8 , suitably by a pyridine, pyrrole or furan ring.
  • an indole or benzofuran ring is formed, this is suitably 5- or 6-linked.
  • a quinolinyl ring is formed, this is suitably 8-linked.
  • Said rings are optionally substituted, e.g. an indole ring may be suitably optionally substituted, e.g. by one or more C 1 -C 8 -alkyl, e.g. 2,3-dimethyl.
  • R 2 phenyl ring is fused by a 5-6 membered heterocyclyl
  • the ring is suitably fused at R 5 —R 6 , e.g. to form a benzo 1,3-dioxole or a 2,3-Dihydro-benzo[1,4]dioxine group.
  • R 2 is a substituted phenyl
  • suitable substituents from List X are one two, three or four substituents, suitably two or three substituents selected from
  • —O-methylene-R 9 e.g. carboxymethoxy, cyanomethoxy or optionally substituted benzyloxy, e.g. benzyloxy or 2-fluorobenzyloxy, (ix) —O—(C 2 -C 4 -alkylene)-R 10 , e.g. —O-ethylene or propylene —R 10 , e.g.
  • dimethylaminopropylaminomethyl (xi) halogen, e.g. fluoro, chloro or bromo, (xii) formyl, (xiii) C 1 -C 8 -alkylcarbonyl, e.g. acetyl, (xiv) C 1 -C 8 -alkylaminocarbonyl, e.g. methylaminocarbonyl, isopropylaminocarbonyl or isobutylaminocarbonyl, (xv) di-C 1 -C 8 -alkylaminocarbonyl, e.g.
  • dimethylaminocarbonyl (xvi) C 1 -C 8 -alkylcarbonylamino, e.g. methylcarbonylamino, (xvii) C 1 -C 8 -alkylsulfonylamino, e.g. methylsulfonylamino, (xviii) hydroxysulfonyl, (xix) C 1 -C 8 -alkylsulfonyl, e.g. methylsulfonyl, (xx) C 1 -C 8 -alkylaminosulfonyl, e.g.
  • methylaminosulfonyl or isopropylaminosulfonyl (xxi) di-C 1 -C 8 -alkylaminosulfonyl, e.g. dimethylaminosulfonyl, (xxii) C 1 -C 8 -alkyl substituted by hydroxy, e.g. hydroxymethyl, (xxiii) C 1 -C 8 -alkoxy substituted by one or more, e.g. three halogens, e.g. fluoro, e.g. trifluoromethoxy, and (xxiv) amino.
  • di-C 1 -C 8 -alkylaminosulfonyl e.g. dimethylaminosulfonyl
  • C 1 -C 8 -alkyl substituted by hydroxy e.g. hydroxymethyl
  • C 1 -C 8 -alkoxy substituted by one or more e.g. three halogens, e.g.
  • R 9 suitably represents carboxy, cyano or phenyl, optionally substituted, e.g. by halogen, e.g. fluoro, e.g. 2-fluoro.
  • R 10 suitably represents hydroxyl, C 1 -C 4 -alkoxy, an N-linked 5-6 membered heteroaryl group, e.g. N-imidazolyl or an N-linked 5-6 membered heterocycly, e.g. N-pyrrolidyl or N-morpholino.
  • R 13 is suitably hydrogen.
  • R 14 is suitably di-C 1 -C 8 -alkylamino, e.g. dimethylamino.
  • R 4 —R 8 may be substituted by any combination of selections of the following suitable substituents, suitably one, two, three or four of R 4 —R 8 , more suitably two or three.
  • R 4 is suitably selected from hydrogen, C 1 -C 8 -alkoxy, e.g. methoxy or n-propoxy and halogen, e.g. fluoro.
  • R 5 is suitably selected from hydrogen, hydroxyl, cyano, formyl, C 1 -C 8 -haloalkyl, e.g. trifluoromethyl, carboxy, C 1 -C 8 -alkoxy, e.g. methoxy, halogen, e.g. fluoro, chloro or bromo, C 1 -C 8 -alkylcarbonyl, e.g. acetyl, C 1 -C 8 -alkylaminocarbonyl, e.g. methylaminocarbonyl, isopropylaminocarbonyl or isobutylcarbonyl, di-C 1 -C 8 -alkylaminocarbonyl, e.g.
  • dimethylaminocarbonyl C 1 -C 8 -alkylsulfonylamino, e.g. methylsulfonylamino, C 1 -C 8 -thioalkyl, C 1 -C 8 -alkylsulfinyl, C 1 -C 8 -alkylsulfonyl, e.g. methylsulfonyl, —(C 0 -C 4 -alkylene)-N(R 13 )—(C 2 -C 4 -alkylene)-R 14 , e.g. dimethylaminopropylaminomethyl, C 1 -C 8 -alkyl substituted by hydroxy, e.g. hydroxymethyl, and hydroxysulfonyl.
  • R 6 is suitably selected from hydrogen, hydroxyl, cyano, nitro, formyl, carboxy, C 1 -C 8 -alkyl, e.g. methyl or isobutyl, C 1 -C 8 -alkoxy e.g. methoxy, ethoxy or isopropoxy, —O—(C 1 -C 4 -alkylene)-R 9 , suitably —O-methylene-R 9 , e.g. benzyloxy or cyanomethoxy, —(C 2 -C 4 -alkylene)-R 10 , suitably —O-ethylene or propylene —R 10 , e.g.
  • fluoro
  • R 7 is suitably selected from hydrogen, hydroxyl, formyl, C 1 -C 8 -alkoxy, e.g. methoxy, halogen, e.g. bromo, chloro or fluoro, —O—(C 1 -C 4 -alkylene)-R 9 , e.g. carboxymethoxy, C 1 -C 8 -alkylcarbonylamino, e.g. methylcarbonylamino, and di-C 1 -C 8 -alkylaminosulfonyl, e.g. dimethylaminosulfonyl.
  • R 8 is suitably selected from hydrogen, hydroxyl, C 1 -C 8 -alkoxy, e.g. methoxy, —(C 2 -C 4 -alkylene)-R 10 , e.g. —O-ethylene—R 10 , e.g. hydroxyethoxy, and —O—(C 1 -C 4 -alkylene)-R 9 , suitably —O-methylene-R 9 , e.g. benzyloxy.
  • R 4 is selected from hydrogen, methoxy, n-propoxy and fluoro.
  • R 5 is selected from hydrogen, hydroxyl, cyano, formyl, trifluoromethyl, carboxy, methoxy, fluoro, chloro, bromo, acetyl, methylaminocarbonyl, isopropylaminocarbonyl, isobutylcarbonyl, dimethylaminocarbonyl, methylsulfonylamino, methylsulfonyl, dimethylaminopropylaminomethyl hydroxymethyl and hydroxysulfonyl.
  • R 6 selected from hydrogen, hydroxyl, cyano, nitro, formyl, carboxy, methyl, isobutyl, methoxy, ethoxy, isopropoxy, benzyloxy, cyanomethoxy, N-pyrrolidylethoxy, imidazolylethoxy, N-morpholinoethoxy, methoxyethoxy, hydroxyethoxy, hydroxypropoxy, N-morpholinopropoxy, fluoro, chloro, acetyl, amino, isopropylaminocarbonyl, methylsulfonylamino, methylsulfonyl and trifluoromethoxy,
  • R 7 is selected from hydrogen, hydroxyl, formyl, methoxy, bromo, chloro, fluoro, carboxymethoxy, methylcarbonylamino and dimethylaminosulfonyl.
  • R 8 is selected from hydrogen, hydroxyl, methoxy, hydroxyethoxy and benzyloxy.
  • R 2 is phenyl
  • a preferred substitution pattern is where R 2 is substituted by at least a fluoro group at R 5 .
  • R 2 is
  • R 3 is suitably hydrogen, amino or methylamino, preferably amino.
  • Y is suitably Y hydrogen, or Y represents the group N(R 15 )R 16 , where R 15 is suitably hydrogen and R 16 is suitably C 1 -C 4 alkyl, e.g. methyl or ethyl, substituted by an optionally substituted phenyl or 56 membered heterocyclyl group, e.g.
  • Y is hydrogen, benzylamino or morpholin-4-yl-ethylamino, most suitably hydrogen.
  • a sub-formula of the present invention is represented by a compound of formula (IB)
  • R 1b is methyl
  • R 2b is phenyl substituted by one two, three or four substituents, suitably two or three substituents selected from hydroxyl, cyano, nitro, halogen, formyl, amino.
  • a suitable individual compound of the invention is selected from:
  • compositions represented by formula I are capable of forming acid addition salts, particularly pharmaceutically acceptable acid addition salts.
  • Pharmaceutically acceptable acid addition salts of the compound of formula I include those of inorganic acids, for example, hydrohalic acids such as hydrofluoric acid, hydrochloric acid, hydrobromic acid or hydroiodic acid, nitric acid, sulfuric acid, phosphoric acid; and organic acids, for example aliphatic monocarboxylic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid and butyric acid, aliphatic hydroxy acids such as lactic acid, citric acid, tartaric acid or malic acid, dicarboxylic acids such as maleic acid or succinic acid, aromatic carboxylic acids such as benzoic acid, p-chlorobenzoic acid, diphenylacetic acid or triphenylacetic acid, aromatic hydroxy acids such as o-hydroxybenzoic acid, p-hydroxybenzoic acid, 1-hydroxynaphthalene-2-car
  • Compounds of formula I which contain acidic, e.g. carboxyl, groups, are also capable of forming salts with bases, in particular pharmaceutically acceptable bases such as those well known in the art; suitable such salts include metal salts, particularly alkali metal or alkaline earth metal salts such as sodium, potassium, magnesium or calcium salts, or salts with ammonia or pharmaceutically acceptable organic amines or heterocyclic bases such as ethanolamines, benzylamines or pyridine. These salts may be prepared from compounds of formula I by known salt-forming procedures.
  • the compounds exist in individual optically active isomeric forms or as mixtures thereof, e.g. as racemic or diastereomeric mixtures.
  • the present invention embraces both individual optically active R and S isomers as well as mixtures, e.g. racemic or diastereomeric mixtures, thereof.
  • the invention provides, in another aspect, a process (A) for preparing a compound of formula I, where R 1 , R 2 and Y are as hereinbefore described and R 3 is NH 2 or C 1 -C 3 -alkylamino, by reaction of a compound of formula (II)
  • Y, R 1 and R 3 are as hereinbefore described and X represents a suitable boronic acid coupling group, e.g. bromo or chloro, with a compound of R 2 —(BOH) 2 under suitable boronic acid coupling conditions, such as Pd(0) tetrakis triphenylphosphine in 1,4-dioxane-water in the presence of a base such as sodium carbonate.
  • suitable boronic acid coupling conditions such as Pd(0) tetrakis triphenylphosphine in 1,4-dioxane-water in the presence of a base such as sodium carbonate.
  • the reaction may be carried out using conventional or microwave radiation heating.
  • X is Br and R 1 is Me, with ammonia or C 1 -C 3 alkylamino in an organic solvent such as tetrahydrofuran (THF) or 1,4-dioxane, as described in WO2005074603 and WO 2003029209.
  • THF tetrahydrofuran
  • 1,4-dioxane 1,4-dioxane
  • compounds of formula (I), where R 3 is amino or C 1 -C 3 -alkylamino can be prepared by reaction of a compound of formula (IV) where Y, R 1 and R 2 are as hereinbefore described, with ammonia or C 1 -C 3 -alkylamino in an organic solvent.
  • Compounds of formula (IV) may be prepared from compounds of formula (V), where Y, R 1 and R 2 are as hereinbefore described, by oxidation of the sulphide group using standard procedures for oxidising sulfides to sulfones.
  • Compounds of formula V may be prepared from compounds of formula (VI), where Y and R 1 are hereinbefore described and X represents a suitable boronic acid coupling group, e.g. triflate or the known bromo analogue, according to WO2003029209.
  • a compound of formula (VII) may be prepared by reaction of a compound of formula (VIII)
  • PI 3-kinase phosphatidylinositol 3-kinase
  • p110? gamma isoform
  • GST glutathione S-transferase
  • Sf9 Spodoptera frugiperda 9
  • Sf9 cells are routinely maintained at densities between 3 ⁇ 10 5 and 3 ⁇ 10 6 cells/ml in serum containing TNMFH medium (Sigma).
  • Sf9 cells at a density of 2 ⁇ 10 6 are infected with human GST-PI 3-K?? 34 baculovirus at a multiplicity of infection (m.o.i.) of 1 for 72 hours.
  • Sf9 cells (1 ⁇ 10 9 ) are resuspended in 100 ml cold (4° C.) lysis buffer (50 mM Tris-HCl pH 7.5, 1% Triton X-100, 150 mM NaCl, 1 mM NaF, 2 mM DTT and protease inhibitors. Cells are incubated on ice for 30 minutes then centrifuged at 15000 g for 20 minutes at 4° C. Purification of the supernatant sample is carried out at 4° C.
  • a cell lysate/GST resin ratio of 50:1 is used.
  • the GST resin is firstly pre-rinsed to remove ethanol preservative and then equilibrated with lysis buffer.
  • Cell lysate (supernatant) is added (usually as 50 ml lysate to 1 ml GST resin in 50 ml tubes) and gently rotated on a mixer at 4° C. for 2-3 hours.
  • the unbound flow through sample is collected by centrifugation at 1000 g for 5 minutes at 4° C. using a DENLEYTM centrifuge.
  • the 1 ml GST resin containing bound material is transferred to a 15 ml FALCONTM centrifuge tube for subsequent washing and elution steps.
  • a series of 3 cycles of washings (mixing by gentle inversion) is performed with 15 ml ice cold wash Buffer A (50 mM Tris-HCl pH 7.5, 1% Triton X-100, 2 mM DTT) interspersed with centrifugation at 1000 g for 5 minutes at 4° C.
  • a final single wash step is performed with 15 ml ice cold wash Buffer B (50 mM Tris-HCl pH 7.5, 2 mM DTT) and then centrifuged at 1000 g for 5 minutes at 4° C.
  • the washed GST resin is finally eluted with 4 cycles of 1 ml ice cold elution buffer (50 mM Tris-HCl pH 7.5, 10 mM reduced glutathione, 2 mM DTT, 150 mM NaCl, 1 mM NaF, 50% ethylene glycol and protease inhibitors) interspersed with centrifugation at 1000 g for 5 minutes at 4° C. Samples are aliquoted and stored at ⁇ 20° C.
  • 1 ml ice cold elution buffer 50 mM Tris-HCl pH 7.5, 10 mM reduced glutathione, 2 mM DTT, 150 mM NaCl, 1 mM NaF, 50% ethylene glycol and protease inhibitors
  • Each well contains 10 ⁇ l test compound in 5% dimethylsulphoxide and 20 ⁇ l assay mix (40 mM Tris, 200 mM NaCl, 2 mM ethyleneglycol-aminoethyl-tetraacetic acid (EGTA), 15 ⁇ g/ml phosphatidylinositol, 12.5 ⁇ M adenosine triphosphate (ATP), 25 mM MgCl 2 , 0.1 ⁇ Ci [ 33 P]ATP).
  • the reaction is started by the addition of 20 ⁇ l of enzyme mix (40 mM Tris, 200 mM NaCl, 2 mM EGTA containing recombinant GST-p110?).
  • the plate is incubated at room temperature for 60 minutes and the reaction terminated by the adding 150 ⁇ l of WGA-bead stop solution (40 mM Tris, 200 mM NaCl, 2 mM EGTA, 1.3 mM ethylene diamine tetraacetic acid (EDTA), 2.6 ⁇ M ATP and 0.5 mg of Wheat Germ Agglutinin-SPA beads (Amersham Biosciences) to each well.
  • WGA-bead stop solution 40 mM Tris, 200 mM NaCl, 2 mM EGTA, 1.3 mM ethylene diamine tetraacetic acid (EDTA), 2.6 ⁇ M ATP and 0.5 mg of Wheat Germ Agglutinin-SPA beads (Amersham Biosciences) to each well.
  • WGA-bead stop solution 40 mM Tris, 200 mM NaCl, 2 mM EGTA, 1.3 mM ethylene diamine tetraacetic acid (EDTA),
  • agents of the invention are useful in the treatment of conditions which are mediated by the activation of the PI 3-kinase enzymes, particularly inflammatory or allergic conditions. Treatment in accordance with the invention may be symptomatic or prophylactic.
  • agents of the invention are useful in the treatment of inflammatory or obstructive airways diseases, resulting, for example, in reduction of tissue damage, airways inflammation, bronchial hyperreactivity, remodelling or disease progression.
  • Inflammatory or obstructive airways diseases to which the present invention is applicable include asthma of whatever type or genesis including both intrinsic (non-allergic) asthma and extrinsic (allergic) asthma, mild asthma, moderate asthma, severe asthma, bronchitic asthma, exercise-induced asthma, occupational asthma and asthma induced following bacterial infection.
  • Treatment of asthma is also to be understood as embracing treatment of subjects, e.g.
  • Prophylactic efficacy in the treatment of asthma will be evidenced by reduced frequency or severity of symptomatic attack, e.g. of acute asthmatic or bronchoconstrictor attack, improvement in lung function or improved airways hyperreactivity. It may further be evidenced by reduced requirement for other, symptomatic therapy, i.e. therapy for or intended to restrict or abort symptomatic attack when it occurs, for example anti-inflammatory (e.g. corticosteroid) or bronchodilatory.
  • Prophylactic benefit in asthma may in particular be apparent in subjects prone to “morning dipping”. “Morning dipping” is a recognised asthmatic syndrome, common to a substantial percentage of asthmatics and characterised by asthma attack, e.g. between the hours of about 4 to 6 am, i.e. at a time normally substantially distant form any previously administered symptomatic asthma therapy.
  • inflammatory or obstructive airways diseases and conditions to which the present invention is applicable include acute lung injury (ALI), adult/acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary, airways or lung disease (COPD, COAD or COLD), including chronic bronchitis or dyspnea associated therewith, emphysema, as well as exacerbation of airways hyperreactivity consequent to other drug therapy, in particular other inhaled drug therapy.
  • the invention is also applicable to the treatment of bronchitis of whatever type or genesis including, e.g., acute, arachidic, catarrhal, croupus, chronic or phthinoid bronchitis.
  • pneumoconiosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
  • pneumoconiosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
  • aluminosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
  • aluminosis anthracosis
  • asbestosis chalicosis
  • ptilosis ptilosis
  • siderosis silicosis
  • tabacosis tabacosis and byssinosis.
  • agents of the invention are also useful in the treatment of eosinophil related disorders, e.g. eosinophilia, in particular eosinophil related disorders of the airways (e.g.
  • eosinophilic infiltration of pulmonary tissues including hypereosinophilia as it effects the airways and/or lungs as well as, for example, eosinophil-related disorders of the airways consequential or concomitant to Löffler's syndrome, eosinophilic pneumonia, parasitic (in particular metazoan) infestation (including tropical eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa (including Churg-Strauss syndrome), eosinophilic granuloma and eosinophil-related disorders affecting the airways occasioned by drug-reaction.
  • Agents of the invention are also useful in the treatment of inflammatory or allergic conditions of the skin, for example psoriasis, contact dermatitis, a topic dermatitis, alopecia areata, erythema multiforma, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, lupus erythematosus, pemphisus, epidermolysis bullosa acquisita, and other inflammatory or allergic conditions of the skin.
  • Agents of the invention may also be used for the treatment of other diseases or conditions, in particular diseases or conditions having an inflammatory component, for example, treatment of diseases and conditions of the eye such as conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis, diseases affecting the nose including allergic rhinitis, and inflammatory disease in which autoimmune reactions are implicated or having an autoimmune component or aetiology, including autoimmune haematological disorders (e.g.
  • haemolytic anaemia haemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia
  • systemic lupus erythematosus polychondritis, sclerodoma, Wegener granulamatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (e.g.
  • ulcerative colitis and Crohn's disease endocrine ophthalmopathy
  • Grave's disease sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, primary billiary cirrhosis, uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis and glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or minal change nephropathy).
  • Other diseases or conditions which may be treated with agents of the invention include thrombosis, hypertension, heart ischaemia and pancreatitis, (Nature review November 2006 Vol 5), treatment of anaemia including haemolytic anaemia, aplastic anaemia and pure red cell anaemia (WO 2006/040318), septic shock, rheumatoid arthritis, osteoarthritis, proliferative diseases such as cancer, atherosclerosis, allograft rejection following transplantation, stroke, obesity, restenosis, diabetes, e.g.
  • diabetes mellitus type I (juvenile diabetes) and diabetes mellitus type II, diarrheal diseases, ischemia/reperfusion injuries, retinopathy, such as diabetic retinopathy or hyperbaric oxygen-induced retinopathy, and conditions characterised by elevated intraocular pressure or secretion of ocular aqueous humor, such as glaucoma.
  • retinopathy such as diabetic retinopathy or hyperbaric oxygen-induced retinopathy
  • conditions characterised by elevated intraocular pressure or secretion of ocular aqueous humor, such as glaucoma such as glaucoma.
  • an agent of the invention in inhibiting inflammatory conditions, for example in inflammatory airways diseases, may be demonstrated in an animal model, e.g. a mouse or rat model, of airways inflammation or other inflanmmatory conditions, for example as described by Szarka et al, J. Immunol. Methods (1997) 202:49-57; Renzi et al, Am. Rev. Respir. Dis . (1993) 148:932-939; Tsuyuki et al., J. Clin. Invest . (1995) 96:2924-2931; and Cernadas et al (1999) Am. J. Respir. Cell Mol. Biol. 20:1-8.
  • the agents of the invention are also useful as co-therapeutic agents for use in combination with other drug substances such as anti-inflammatory, bronchodilatory or antihistamine drug substances, particularly in the treatment of obstructive or inflammatory airways diseases such as those mentioned hereinbefore, for example as potentiators of therapeutic activity of such drugs or as a means of reducing required dosaging or potential side effects of such drugs.
  • An agent of the invention may be mixed with the other drug substance in a fixed pharmaceutical composition or it may be administered separately, before, simultaneously with or after the other drug substance.
  • the invention includes a combination of an agent of the invention as hereinbefore described with an anti-inflammatory, bronchodilatory or antihistamine drug substance, said agent of the invention and said drug substance being in the same or different pharmaceutical composition.
  • anti-inflammatory drugs include steroids, in particular glucocorticosteroids such as budesonide, beclamethasone dipropionate, fluticasone propionate, ciclesonide or mometasone furoate and compounds described in WO 0200679, WO 0288167, WO 0212266 and WO 02100879, LTB4 antagonists such as those described in U.S. Pat. No.
  • LTD4 antagonists such as montelukast and zafirlukast, dopamine receptor agonists such as cabergoline, bromocriptine, ropinirole and 4-hydroxy-7-[2-[[2-[[342-phenylethoxy)-propyl]-sulfonyl]ethyl]-amino]ethyl]-2(3H)-benzothiazolone and pharmaceutically acceptable salts thereof (the hydrochloride being Viozan®—AstraZeneca), and PDE4 inhibitors such as Ariflo® (GlaxoSmithKline), Roflumilast (Byk Gulden), V-11294A (Napp), BAY19-8004 (Bayer), SCH-351591 (Schering-Plough), Arofylline (Almirall Prodesfarma), PD189659 (Parke-Davis), AWD-12-281 (Asta Medica), CDC-801 (C
  • Such bronchodilatory drugs include anticholinergic or antimuscarinic agents, in particular ipratropium bromide, oxitropium bromide and tiotropium salts but also those described in WO 01/04118, WO 02/51841, WO 02/53564, WO 03/00840, WO 03/87094, WO 04/05285, WO 02/00652, WO 03/53966, EP 424021, U.S. Pat. No. 5,171,744, U.S. Pat. No.
  • beta-2 adrenoceptor agonists such as salbutamol, terbutaline, salmeterol and, especially, formoterol and pharmaceutically acceptable salts thereof, and compounds (in free or salt or solvate form) of formula I of PCT International patent publication No. WO 00/75114, which document is incorporated herein by reference, preferably compounds of the Examples thereof, especially 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one, and pharmaceutically acceptable salts thereof.
  • Co-therapeutic antihistamine drug substances include cetirizine hydrochloride, acetaminophen, clemastine fumarate, promethazine, loratidine, desloratidine, diphenhydramine and fexofenadine hydrochloride.
  • Combinations of agents of the invention and steroids, beta-2 agonists, PDE4 inhibitors or LTD4 antagonists may be used, for example, in the treatment of COPD or, particularly, asthma.
  • Combinations of agents of the invention and anticholinergic or antimuscarinic agents, PDE4 inhibitors, dopamine receptor agonists or LTB4 antagonists may be used, for example, in the treatment of asthma or, particularly, COPD.
  • agents of the invention with anti-inflammatory drugs are those with antagonists of chemokine receptors, e.g. CCR-1, CCR-2, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8, CCR-9 and CCR10, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, particularly CCR-5 antagonists such as Schering-Plough antagonists SC-351125, SCH-55700 and SCH-D, Takeda antagonists such as N—[[4-[[[[6,7-dihydro-2-(4-methylphenyl)-5H-benzocyclohepten-8-yl]carbonyl]amino]phenyl]-methyl]tetrahydro-N,N-dimethyl-2H-pyran-4-aminium chloride (TAK-770), and CCR-5 antagonists described in U.S. Pat. No. 6,166,037 (particularly claims 18 and 19 ), WO00/66558 (particularly claim
  • the agents of the invention may be administered by any appropriate route, e.g. orally, for example in the form of a tablet or capsule; parenterally, for example intravenously; by inhalation, for example in the treatment of inflammatory or obstructive airways disease; intranasally, for example in the treatment of allergic rhinitis; topically to the skin, for example in the treatment of atopic dermatitis; or rectally, for example in the treatment of inflammatory bowel disease.
  • any appropriate route e.g. orally, for example in the form of a tablet or capsule; parenterally, for example intravenously; by inhalation, for example in the treatment of inflammatory or obstructive airways disease; intranasally, for example in the treatment of allergic rhinitis; topically to the skin, for example in the treatment of atopic dermatitis; or rectally, for example in the treatment of inflammatory bowel disease.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula I in free form or in the form of a pharmaceutically acceptable salt, optionally together with a pharmaceutically acceptable diluent or carrier therefore.
  • the composition may contain a co-therapeutic agent such as an anti-inflammatory, bronchodilatory or antihistamine drug as hereinbefore described.
  • a co-therapeutic agent such as an anti-inflammatory, bronchodilatory or antihistamine drug as hereinbefore described.
  • Such compositions may be prepared using conventional diluents or excipients and techniques known in the galenic art.
  • oral dosage forms may include tablets and capsules.
  • Formulations for topical administration may take the form of creams, ointments, gels or transdermal delivery systems, e.g. patches.
  • Compositions for inhalation may comprise aerosol or other atomizable formulations or dry powder formulations.
  • the composition comprises an aerosol formulation
  • it preferably contains, for example, a hydro-fluoro-alkane (HFA) propellant such as HFA134a or HFA227 or a mixture of these, and may contain one or more co-solvents known in the art such as ethanol (up to 20% by weight), and/or one or more surfactants such as oleic acid or sorbitan trioleate, and/or one or more bulking agents such as lactose.
  • HFA hydro-fluoro-alkane
  • the composition comprises a dry powder formulation, it preferably contains, for example, the compound of formula I having a particle diameter up to 10 microns, optionally together with a diluent or carrier, such as lactose, of the desired particle size distribution and a compound that helps to protect against product performance deterioration due to moisture.
  • a diluent or carrier such as lactose
  • the composition comprises a nebulised formulation, it preferably contains, for example, the compound of formula I either dissolved, or suspended, in a vehicle containing water, a co-solvent such as ethanol or propylene glycol and a stabiliser, which may be a surfactant.
  • Dosages of agents of the invention employed in practising the present invention will of course vary depending, for example, on the particular condition to be treated, the effect desired and the mode of administration. In general, suitable daily dosages for oral administration are of the order of 0.1 to 10 mg/kg.
  • Table 1 shows the method of preparation being described hereinafter.
  • Table 2 shows mass spectrometry data.
  • Mass spectra are run on an open access Waters 600/ZQ HPLC/Mass Spectrometer system using electrospray ionization. [M+H] + refers to mono-isotopic molecular weights.
  • the chloro analogue of Intermediate 1 can also be used by an analogous process.
  • Trifluoro-methanesulfonic acid 1-methyl-6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl ester (Intermediate 2) (1.0 g, 3.0 mmol) is dissolved in THF (50 ml), under an inert atmosphere of argon. To this is added Pd(PPh 3 ) 2 Cl 2 (0.1 g, 0.15 mmol) and PPh 3 (0.023 g, 0.09 mmol) simultaneously. A solution of Na 2 CO 3 (0.96 g, 9.1 mmol) dissolved in 5 ml of distilled water is added and the reaction mixture is stirred for 15 minutes at room temperature.
  • 3-(3-Fluoromethoxy-phenyl)-6-methanesulfonyl-1-methyl-1H-pyrazolo[3,4-d]pyrimidine (0.8 g, 2.3 mmol) is dissolved in a saturated solution of ammonia in THF in an autoclave and the reaction mixture is stirred at room temperature for 2-18 hours. The solvent is removed in vacuo and the resulting solid is suspended in methanol, stirred at room temperature for 30 minutes and collected by filtration to afford the title compound as a white solid.
  • Example 46 are prepared analogously to Example 46 from the corresponding phenols and halogenated intermediates.
  • reaction mixture is diluted with EtOAc (100 ml) and washed with water (3 ⁇ 40 ml) and brine (10 ml). The organic portion is dried over MgSO 4 , filtered and concentrated in vacuo. The resulting solid is triturated with hot EtOAc (plus few drops of MeOH), filtered and dried under vacuum at 50° C. for 3 hours to afford the title compound as an off-white solid.
  • This compound is prepared analogously to Example 1, Method A by replacing ammonia in the final step with methylamine to afford the title compound.
  • reaction mixture is treated with DMSO (2 ml) and filtered through a 2 g silica cartridge washing with EtOAc:MeOH (10:1, 4 ml).
  • the filtrate is concentrated in vacuo and the resulting residue is dissolved in NMP (4 ml) and loaded onto an IsoluteTM SCX column (silica based cation exchange sorbent) eluting with MeOH (4 ml) and 1M NH 3 in MeOH (6 ml).
  • IsoluteTM SCX column sica based cation exchange sorbent
  • Example 60 is prepared analogously to Example 60 from the appropriate commercial boronic acids using standard Suzuki coupling methodology.
  • Examples 61-65 are further purified by preparative HPLC (water/acetonitrile, 0.1% TFA) to afford the products as the trifluoroacetate salts.
  • Example 78 are prepared analogously to Example 78 from commercial or prepared boronic acids using standard Suzuki coupling methodology.
  • the compounds are recovered from reaction mixtures and purified using conventional techniques such as, for example, flash chromatography, reverse phase chromatography or preparative HPLC.
  • Example 88 are prepared analogously to Example 88 from commercial boronic acids using standard Suzuki coupling methodology.
  • This compound is prepared analogously to Example 91 by replacing 3-(2-Methoxy-5-trifluoromethylphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine phenyl) (Example 88) with 3-(2,4-Dimethoxy-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine (Example 89).
  • the addition of water during the aqueous quench results in a precipitate but on filtration a gum forms, this gum is therefore triturated with diethyl ether (50 ml) to form a solid, which is collected by filtration and dried under vacuum to afford the title compound.
  • This compound is prepared analogously to Example 91 by replacing 3-(2-Methoxy-5-trifluoromethyl-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine (Example 88) with 3-(S-Chloro-2-methoxy-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine (Example 71) to afford the title compound.
  • reaction mixture is stirred at room temperature for 48 hours and the resulting precipitate is collected by filtration, dissolved in saturated aqueous NaHCO 3 (100 ml) and washed with EtOAc (2 ⁇ 50 ml). The aqueous portion is acidified to pH 1 with 2M HCl resulting in an off-white solid which is collected by filtration and dried under vacuum for 72 hours to afford the title compound.
  • Step 1 3-(4-Benzyloxy-3,5-dichloro-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine
  • This compound is prepared analogously to Example 78 by replacing 3-(N-isopropylaminocarbonyl)benzene boronic acid with 4-(benzyloxy)-3,5 dichlorophenyl boronic acid to afford the title compound.
  • This compound is prepared analogously to Example 78 by replacing 3-(N-isopropylamino carbonyl)benzene boronic acid with 3-Chloro-5-fluoro-4-hydroxyphenyl-boronic acid (Intermediate 8). The reaction is carried out using microwave radiation at 150° C. for 30 minutes.
  • Step 1 3-(5-Chloro-2-methoxy-phenyl)-1-methyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine Trifluoroacetate
  • This compound is prepared analogously to Example 91 by replacing 3-(2-Methoxy-5-trifluoromethyl-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine (Example 88) with 3-(6-Amino-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-methoxy-benzaldehyde (Example 75) to afford the title compound.
  • This compound is prepared analogously to Example 101 by replacing S-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-3-trifluoromethyl-pyridin-2-ylamine (Intermediate 10) with 2,6-difluoro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzonitrile (Intermediate 11). Purification by preparative HPLC (water/acetonitrile, 0.1% TFA) affords the title compound as the trifluoroacetate salt.
  • This compound is prepared analogously to Example 78 by replacing 4-(N-isopropylamino carbonyl)phenylboronic acid with N-[3-Fluoro-2-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]acetamide (Intermediate 12) to afford the title compound.
  • reaction mixture is filtered through Celite® (filter agent) washing with MeOH, the filtrate is concentrated in vacuo and purification of the resulting residue is by preparative HPLC (water/acetonitrile, 0.1% TFA) affords the title compound as a white solid.
  • This compound is prepared analogously to Example 88 by replacing 2-methoxy-5-trifluoromethylphenylboronic acid with 4-Fluoro-2-methoxyphenylboronic acid to afford the title compound.
  • This compound is prepared analogously to Example 88 by replacing 5-trifluoro methyl-2-methoxybenzene boronic acid with 4-methoxy-3-trifluoromethylphenyl boronic acid to afford the title compound.
  • Step 1 3-(3-Fluoro-2-methoxy-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine
  • This compound is prepared analogously to Example 88 by replacing 2-methoxy-5-trifluoromethylphenylboronic acid with 3-fluoro-2-methoxyphenylboronic acid to afford the title compound.
  • This compound is prepared analogously to Example 111 (step 2) by replacing 3-(4-methoxy-3-trifluoromethyl-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine with 3-(3-Fluoro-2-methoxy-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine to afford the title compound.
  • Step 1 3-(3-Chloro-4-ethoxy-5-trifluoromethyl-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine
  • Step 2 4-(6-Amino-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chloro-6-trifluoro methyl-phenol
  • This compound is prepared analogously to Example 108 by replacing 3-(3,5-Difluoro-4-methoxy-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine (Example 98) with 3-(3-Chloro-4-methoxy-5-trifluoromethyl-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine sulfate (product from step 1) to afford the title compound.
  • This compound is prepared analogously to Example 97 (step 2) by replacing 2-(6-Amino-1-methyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4-chloro-phenol with 3-(5-Chloro-2,4-dimethoxy-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine (Example 114) to afford the title compound.
  • This compound is prepared analogously to Example 91 by replacing 3-(2-Methoxy-5-trifluoromethyl-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine (Example 88) with 3-(3-Chloro-2-methoxy-5-trifluoromethyl-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine (Example 118) to afford the title compound.
  • This compound is prepared analogously to Example 88 by replacing 2-methoxy-5-trifluoromethylphenylboronic acid with 2-methoxy-4-(trifluoromethoxy)-phenylboronic acid to afford the title compound.
  • This compound is prepared analogously to Example 118 by replacing methoxy-4-trifluoromethyl-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine (Example 88) with 3-(2-Methoxy-4-trifluoromethoxy-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine (Example 123) to afford the title compound as the sulphate salt.
  • Example 123 This compound is prepared analogously to Example 124 by replacing 3-(2-Methoxy-4-trifluoromethoxy-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine (Example 123) with 3-(5-Chloro-2-methoxy-4-trifluoromethoxy-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine (Example 125). Purification by preparative HPLC (water/acetonitrile, 0.1% TFA), affords the title compound as the trifluoroacetate salt.
  • Step 1 5-(6-Amino-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N,N-diethyl-2-methoxy-benzenesulfonamide
  • This compound is prepared analogously to Example 88 by replacing 2-methoxy-5-trifluoromethylphenylboronic acid with 4-methoxy-3-(N,N-diethylsulfonyl)benzeneboronic acid to afford the title compound.
  • This compound is prepared analogously to Example 124 by replacing 3-(2-Methoxy-4-trifluoromethoxy-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine (Example 123) with 5-(6-Amino-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N,N-diethyl-2-methoxy-benzenesulfonamide and by using 20 eq of BBr 3 in DCM to afford the title as the hydrobromide salt.
  • Step 1 N-[3-(6-Amino-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-phenyl]-methanesulfonamide
  • This compound is prepared analogously to Example 88 by replacing 2-methoxy-5-trifluoromethylphenylboronic acid with 3-(methylsulfonylamino)phenylboronic acid to afford the title compound.
  • This compound is prepared analogously to Example 118 by replacing 3-(2-Methoxy-5-trifluoromethyl-phenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine (Example 88) with N-[3-(6-Amino-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-phenyl]-methanesulfonamide. Purification of the crude residue by preparative HPLC (water/acetonitrile, 0.1% TFA) affords the title compound as the trifluoroacetate salt.
  • This compound is made analogously to Example 88 by replacing 2-methoxy-5-trifluoromethylphenylboronic acid with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)chlorobenzene.
  • the crude residue is stirred with iso-hexanes:EtOAc, the resulting solid is filtered, washed with isohexanes and dried under vacuum to afford the title compound.
  • This compound is prepared analogously to Example 130 by replacing S-(methylsulfonyl)pyridine-3-boronic acid with 5-trifluoromethylpyridine-3-boronic acid (Intermediate 17).
  • the resulting product after reverse phase column chromatography is suspended in MeOH and 4M HCl in 1,4-dioxane (excess) to form the HCl salt. Further purification by trituration of the solid in MeOH/Et 2 O affords the title compound.
  • This compound is prepared analogously to Example 88 by replacing 3-Bromo-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine (Intermediate 3) with N*4*-Benzyl-3-bromo-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Intermediate 15) and by replacing 2-methoxy-5-trifluoromethylphenylboronic acid with 3-fluoro-4-methoxyphenylboronic acid to afford the title compound.
  • This compound is prepared analogously to Example 88 by replacing 3-Bromo-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine (Intermediate 3) with 3-Bromo-1-methyl-N*4*-(2-morpholin-4-yl-ethyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine (Intermediate 16) and by replacing 2-methoxy-5-trifluoromethylphenylboronic acid with 2,6-dichloro-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenol to afford the title compound.
  • 2-Amino-4,6-dichloro-pyrimidine-5-carbaldehyde (5 g, 26.04 mmol) is dissolved in THF (125 ml), Et 3 N (4.13 ml, 29.6 mmol) is added followed by hydrazine monohydrate (1.19 g, 26.04 mmol) in water (15 ml) and the reaction mixture is stirred at room temperature for 1.5 hours. The organic solvent is removed in vacuo and a further 30 ml of water is added to the reaction mixture. The resulting precipitate is collected by filtration and dried under vacuum to afford the title compound.
  • N-bromosuccinimide (673 mg, 3.8 mmol) is added to a suspension of 4-Chloro-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine (500 mg, 2.96 mmol) in dichloroethane (30 ml) and heated to reflux overnight. The reaction mixture is cooled to room temperature and the solvent is removed in vacuo. The resulting solid is diluted with water, stirred for 30 minutes at room temperature, then collected by filtration to afford the title compound.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
US12/227,314 2006-05-23 2007-05-21 Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders Abandoned US20090131457A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0610242.0A GB0610242D0 (en) 2006-05-23 2006-05-23 Organic compounds
GB0610242.0 2006-05-23
PCT/EP2007/004501 WO2007134828A1 (en) 2006-05-23 2007-05-21 Pyrazolo [3, 4-d] pyrimidine derivatives useful to treat respiratory disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/004501 A-371-Of-International WO2007134828A1 (en) 2006-05-23 2007-05-21 Pyrazolo [3, 4-d] pyrimidine derivatives useful to treat respiratory disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/049,706 Continuation US20140051698A1 (en) 2006-05-23 2013-10-09 Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders

Publications (1)

Publication Number Publication Date
US20090131457A1 true US20090131457A1 (en) 2009-05-21

Family

ID=36687588

Family Applications (5)

Application Number Title Priority Date Filing Date
US12/227,314 Abandoned US20090131457A1 (en) 2006-05-23 2007-05-21 Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders
US14/049,706 Abandoned US20140051698A1 (en) 2006-05-23 2013-10-09 Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders
US14/261,890 Active US8901134B2 (en) 2006-05-23 2014-04-25 Pyrazolo [3,4-D] pyrimidine derivatives useful to treat respiratory disorders
US15/194,373 Abandoned US20160303132A1 (en) 2006-05-23 2016-06-27 Pyrazolo [3,4-d] pyrimidine derivatives useful to treat respiratory disorders
US15/867,425 Abandoned US20180125849A1 (en) 2006-05-23 2018-01-10 Pyrazolo [3,4-d] pyrimidine derivatives useful to treat respiratory disorders

Family Applications After (4)

Application Number Title Priority Date Filing Date
US14/049,706 Abandoned US20140051698A1 (en) 2006-05-23 2013-10-09 Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders
US14/261,890 Active US8901134B2 (en) 2006-05-23 2014-04-25 Pyrazolo [3,4-D] pyrimidine derivatives useful to treat respiratory disorders
US15/194,373 Abandoned US20160303132A1 (en) 2006-05-23 2016-06-27 Pyrazolo [3,4-d] pyrimidine derivatives useful to treat respiratory disorders
US15/867,425 Abandoned US20180125849A1 (en) 2006-05-23 2018-01-10 Pyrazolo [3,4-d] pyrimidine derivatives useful to treat respiratory disorders

Country Status (24)

Country Link
US (5) US20090131457A1 (es)
EP (1) EP2026811A1 (es)
JP (1) JP2009537580A (es)
KR (1) KR101106853B1 (es)
CN (1) CN101443013A (es)
AR (2) AR061057A1 (es)
AU (1) AU2007253615B2 (es)
BR (1) BRPI0712022A2 (es)
CA (1) CA2650661A1 (es)
CL (1) CL2007001455A1 (es)
CR (1) CR10419A (es)
EC (1) ECSP088902A (es)
GB (1) GB0610242D0 (es)
GT (1) GT200800256A (es)
IL (1) IL195017A0 (es)
MA (1) MA30433B1 (es)
MX (1) MX2008014835A (es)
NO (1) NO20084997L (es)
PE (1) PE20080315A1 (es)
RU (1) RU2008150619A (es)
TN (1) TNSN08478A1 (es)
TW (1) TW200806665A (es)
WO (1) WO2007134828A1 (es)
ZA (1) ZA200809097B (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074722A1 (en) * 2008-09-19 2010-03-25 Panasonic Corporation Part mounting device
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
WO2013174794A1 (en) 2012-05-23 2013-11-28 F. Hoffmann-La Roche Ag Compositions and methods of obtaining and using endoderm and hepatocyte cells

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520744A (ja) 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
KR20130087054A (ko) 2006-04-04 2013-08-05 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
EP2173722B1 (en) * 2007-07-26 2012-08-29 Novartis AG Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
TW200911798A (en) 2007-08-02 2009-03-16 Amgen Inc PI3 kinase modulators and methods of use
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
CA2710194C (en) 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
MX358640B (es) 2008-01-04 2018-08-29 Intellikine Llc Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
EP2111861A1 (en) * 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
US9096611B2 (en) * 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
JP5819195B2 (ja) 2008-10-16 2015-11-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 融合環ヘテロアリールキナーゼ阻害剤
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
EP2414361A1 (en) 2009-03-31 2012-02-08 ArQule, Inc. Substituted heterocyclic compounds
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
US20110081316A1 (en) * 2009-10-02 2011-04-07 Vertex Pharmaceuticals Incorporated Pyrazole inhibitors of phosphatidylinositol 3-kinase
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
TWI546305B (zh) 2011-01-10 2016-08-21 英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
EP2678018A4 (en) 2011-02-23 2015-09-30 Intellikine Llc COMBINATION OF CHINESE HEMMER AND USES THEREOF
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
GB201115853D0 (en) 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
IN2014DN01883A (es) 2011-09-14 2015-05-15 Proximagen Ltd
BR112014007788A2 (pt) 2011-10-03 2017-04-18 Univ North Carolina Chapel Hill compostos de pirrolopirimidina para tratamento do câncer
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2014013632A (es) 2012-05-22 2015-02-05 Univ North Carolina Compuestos de pirimidina para el tratamiento de cancer.
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
RU2015115631A (ru) 2012-09-26 2016-11-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Модулирование ire1
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
CN105102000B (zh) 2012-11-01 2021-10-22 无限药品公司 使用pi3激酶亚型调节剂的癌症疗法
WO2014085225A1 (en) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EA201691872A1 (ru) 2014-03-19 2017-04-28 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
US9603850B2 (en) 2014-04-11 2017-03-28 The University Of North Carolina At Chapel Hill MerTK-specific pyrazolopyrimidine compounds
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CZ308056B6 (cs) * 2015-07-20 2019-11-27 Ustav Experimentalni Botaniky Av Cr V V I 5-Substituované-7-[4-(substituované)benzyl]amino-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako antirevmatika, a farmaceutické přípravky
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
SG11201808878UA (en) 2016-04-15 2018-11-29 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
EP3442535B1 (en) 2016-04-15 2022-06-01 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
US20230121698A1 (en) * 2019-12-23 2023-04-20 Sanford Burnham Prebys Medical Discovery Institute Ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) modulators and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001230A (en) * 1974-05-13 1977-01-04 Eli Lilly And Company 3-(5-Nitroimidazol-2-yl)pyrazolo[3,4-d]pyrimidine compounds
US4044130A (en) * 1974-07-03 1977-08-23 Ciba-Geigy Corporation Compositions for the control of microorganisms
US6518277B1 (en) * 2000-04-25 2003-02-11 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR205429A1 (es) * 1971-04-27 1976-05-07 Ciba Geigy Ag Procedimiento para la elaboracion de nuevos derivados de 4-amino - 3-(5-nitro- 2 -furil)-1-metil - 1h - pirazol-(3,4-ol)-pirimidina
JPS5195094A (en) * 1975-01-31 1976-08-20 * ***** ****so*shi***** *o*u****** ********ne***u**** *** *** ****ne*** *************te***ku**
AU780358B2 (en) * 1999-06-08 2005-03-17 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
PT1212327E (pt) * 1999-09-17 2004-01-30 Abbott Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos
DE60228103D1 (de) * 2001-10-02 2008-09-18 Smithkline Beecham Corp Chemische verbindungen
WO2003082341A1 (en) 2002-03-22 2003-10-09 Cellular Genomics, Inc. AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO[3,4-d] PYRIMIDINES AS KINASE MODULATORS
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
CA2553724A1 (en) * 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
JP2008520744A (ja) * 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
EA200870385A1 (ru) * 2006-03-29 2009-04-28 Фолдркс Фармасьютикалз, Инк. Ингибирование токсичности альфа-синуклеина

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001230A (en) * 1974-05-13 1977-01-04 Eli Lilly And Company 3-(5-Nitroimidazol-2-yl)pyrazolo[3,4-d]pyrimidine compounds
US4044130A (en) * 1974-07-03 1977-08-23 Ciba-Geigy Corporation Compositions for the control of microorganisms
US6518277B1 (en) * 2000-04-25 2003-02-11 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074722A1 (en) * 2008-09-19 2010-03-25 Panasonic Corporation Part mounting device
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
WO2013174794A1 (en) 2012-05-23 2013-11-28 F. Hoffmann-La Roche Ag Compositions and methods of obtaining and using endoderm and hepatocyte cells

Also Published As

Publication number Publication date
JP2009537580A (ja) 2009-10-29
CN101443013A (zh) 2009-05-27
KR101106853B1 (ko) 2012-01-19
CA2650661A1 (en) 2007-11-29
KR20090008392A (ko) 2009-01-21
BRPI0712022A2 (pt) 2011-12-27
US20140051698A1 (en) 2014-02-20
US8901134B2 (en) 2014-12-02
MX2008014835A (es) 2008-12-01
NO20084997L (no) 2008-12-22
AR110051A2 (es) 2019-02-20
US20160303132A1 (en) 2016-10-20
ECSP088902A (es) 2008-12-30
GB0610242D0 (en) 2006-07-05
CL2007001455A1 (es) 2008-05-16
AU2007253615A1 (en) 2007-11-29
GT200800256A (es) 2009-05-28
IL195017A0 (en) 2009-08-03
CR10419A (es) 2011-07-19
US20180125849A1 (en) 2018-05-10
US20140235632A1 (en) 2014-08-21
PE20080315A1 (es) 2008-06-11
RU2008150619A (ru) 2010-06-27
TNSN08478A1 (en) 2010-04-14
ZA200809097B (en) 2009-11-25
AU2007253615B2 (en) 2011-06-23
MA30433B1 (fr) 2009-05-04
EP2026811A1 (en) 2009-02-25
TW200806665A (en) 2008-02-01
WO2007134828A1 (en) 2007-11-29
AR061057A1 (es) 2008-07-30

Similar Documents

Publication Publication Date Title
US8901134B2 (en) Pyrazolo [3,4-D] pyrimidine derivatives useful to treat respiratory disorders
EP2139892B1 (en) Substituted pyrimidodiazepines useful as plk1 inhibitors
US7109202B2 (en) Aminothaizoles and their use as adenosine receptor antagonists
EP2551270B1 (en) Pyrazolopyrimidine derivatives for use as pi3 kinase antagonists
EP2157091B1 (en) Inhibitors of phosphatidylinositol 3-kinase
US8017605B2 (en) P38 kinase inhibiting agents
US20110009429A1 (en) Heterocyclic compounds as inhibitors of cxcr2
EP2173722B1 (en) Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
US20080269335A1 (en) Crth2 Receptor Antagonists
US8263585B2 (en) Organic compounds
KR20090125774A (ko) 신규한 아데닌 화합물
NZ516667A (en) Purine derivatives inhibitors of tyrosine protein kinase syk
US20230406858A1 (en) Tyk2 pseudokinase ligands
KR20090080998A (ko) Ｃｘｃｒ2 길항제로서의 5-술파닐메틸-[1,2,4]트리아졸[1,5-ａ]피리미딘-7-올 유도체
EP2451787B1 (en) Polymorph of [4,6-bis(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl]
KR20060129276A (ko) Ａ２ｂ 길항제로서의 티아졸 유도체
CN101326185A (zh) 芳基乙酸和酯衍生物及其作为抗炎剂的应用
US20140113917A1 (en) Pyrazole compounds as crth2 antagonists
WO2020147097A1 (zh) 一种新型的脂质体激酶抑制剂
US7468370B2 (en) [1,7]naphthyridines as PDE4 inhibitors
US8778946B2 (en) 3-substituted-6-(pyridinylmethoxy)-pyrrolopyridine compounds
US20120302584A1 (en) Novel salts forms of pyrimidin-5-yl acetic acid derivative
US20110294828A1 (en) Process for preparing a polymorph of the choline salt of a pyrimidin-5-yl acetic acid derivative
HK1139936B (en) Substituted pyrimidodiazepines useful as plk1 inhibitors
HK1178161B (en) Pyrazolopyrmidine derivatives for use as pi3 kinase antagonists

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRUCE, IAN;HAYLER, JUDY FOX;BLOOMFIELD, GRAHAM CHARLES;AND OTHERS;SIGNING DATES FROM 20070315 TO 20070329;REEL/FRAME:024917/0364

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION